Table 2.

Case reports associating nivolumab therapy with nephrotoxic reactions.

Author	Patients	Age	Gender	ICPI	Cancer	Renal biopsy	Treatment	Outcome
Hoffman et al. [9]	1	52 yrs	M	Nivolumab	Melanoma	Not available	Steroids	Recovery
Shirali et al. [13]	6	67.5 yrs	3M/3F	Nivolumab/ Pembrolizumab/ Ipilimumab	NSCLC	Tubulointerstitial inflammation with infiltrate of lymphocytes	Steroids in 5 of 6 patients	Recovery
Kishi et al. [10]	1	72 yrs	M	Nivolumab	NSCLC	IgA nephropathy	No steroids	Recovery
Murakami et al. [12]	1	75 yrs	M	Combination of Nivolumab and Ipilimumab	Melanoma	Tubulointerstitial inflammation with infiltrate of lymphocytes	Steroids	Recovery
Koda et al. [11]	1	67 yrs	M	Nivolumab	NSCLC	Acute tubulointerstitial nephritis without granuloma formation	Steroids	Recovery
Bottlaender et al. [8]	1	76 yrs	F	Ipilumumab-Nivolumab	Melanoma	Interstitial edema with dense inflammatory infiltrates	Steroids	Recovery
Jung et al. [4]	1	70 yrs	M	Nivolumab	Kidney cancer	Diffusive tubular injury and complex-mediated glomerulonephritis	Steroids and hemodialysis	Recovery

ICPI= immune checkpoint inhibitor; NSCLC= non-small cell lung cancer; M= male, F= female.